上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Ursodeoxycholic acid sodium (Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)
Ursodeoxycholic acid (Ursodeoxycholate) sodium 是由肠道细菌转化 (cheno)脱氧胆酸而产生的一种次级胆汁酸,是肠道屏障完整性的关键调节因子,对脂质代谢至关重要。Ursodeoxycholic acid sodium 作为信号分子,通过与胆汁酸激活的受体相互作用发挥作用,包括G蛋白偶联的胆汁酸受体5 (TGR5,GPCR19) 和法尼酯X受体 (FXR)。Ursodeoxycholic acid sodium 可用于多种肝脏和胃肠道疾病的研究。具有口服活性。
Ursodeoxycholic acid sodium Chemical Structure
CAS No. : 2898-95-5
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
500 mg | ¥1000 | In-stock | |
1 g | ¥1800 | In-stock | |
5 g | ¥6300 | In-stock | |
10 g | 询价 | ||
50 g | 询价 |
* Please select Quantity before adding items.
Ursodeoxycholic acid sodium 相关产品
•相关化合物库:
- Natural Product Library Plus
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- Bioactive Compound Library Plus
- GPCR/G Protein Compound Library
- Immunology/Inflammation Compound Library
- Metabolism/Protease Compound Library
- Natural Product Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Drug Repurposing Compound Library
- Lipid Compound Library
- Orally Active Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Gut Microbial Metabolite Library
- Microbial Metabolite Library
- Anti-Obesity Compound Library
- Lipid Metabolism Compound Library
- Rare Diseases Drug Library
生物活性 |
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active[1][2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||||||
体内研究 (In Vivo) |
Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
分子量 |
414.55 |
||||||||||||||||
Formula |
C24H39NaO4 |
||||||||||||||||
CAS 号 |
2898-95-5 |
||||||||||||||||
中文名称 |
熊去氧胆酸钠盐 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 125 mg/mL (301.53 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务